Shots:

• The company reported the 5yr. follow up results of P-III study evaluating SB3 (trastuzumab biosimilar) vs trastuzumab in 875 patients with HER2-positive early or LA breast cancer for 4yrs. post randomization
• The results showed comparable long-term survival results b/w SB3 and trastuzumab after a median follow-up of 68mos. In 5yrs. survival analysis, EFS rate (79.8% & 75.0%), 5yrs. OS was also comparable with OS rate (92.5% & 85.4%)
• In the post-hoc analysis, SB3 was compared with non-drifted trastuzumab which showed an EFS rate (79.8% vs 82.5%), OS rate (92.5% & 91.4%). SB3 was approved in the US under the brand name Ontruzant & is marketed by Organon

Ref: Globe Newswire | Image: Samsung Bioepis